Stablix Therapeutics has launched with $63m in equity financing to commercialise research pioneered in Henry Colecraft’s laboratory at Columbia University.

Stablix Therapeutics, a US-based biotechnology company advancing research from Columbia University, launched yesterday with $63m in series A funding led by Versant Ventures. The round also included Alexandria Venture Investments, the investment arm of life science real estate investment trust Alexandria Real Estate Equities, as well as New Enterprise Associates (NEA), Cormorant Capital and Euclidean…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.